8-K Announcements
6Oct 23, 2026·SEC
May 26, 2026·SEC
Jan 8, 2026·SEC
Neuphoria Therapeutics operates as a high-risk, pre-revenue clinical entity whose financial stability is entirely contingent upon sporadic, non-recurring licensing milestones rather than sustainable commercial operations.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 18, 2026 | -$0.56+0.0% vs -$0.56 | $1M+17.4% vs $996,483 |
Q4 2026 Sep 2, 2026 | -$0.56+0.0% vs -$0.56 | $1M+0.0% vs $1M |
Q2 2026 May 15, 2026 | -$0.09+83.9% vs -$0.56 | — vs — |
Q1 2026 Feb 17, 2026 | -$0.77-37.5% vs -$0.56 | — vs — |
Benchmark NEUP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neuphoria Therapeutics Inc. (NEUP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.28 | $12.32M | -2.48 | -92.5% | -423.32% | -18.55% | — | |
| $17.83 | $3.05B | 8.64 | 11.87% | 30.13% | 28.03% | — | |
| $18.40 | $1.36B | 6.86 | 18.52% | 43.79% | 15.84% | — | |
| $305.19 | $8.51B | -24.78 | -100% | — | -29.41% | — | |
| $251.41 | $37.15B | 106.78 | 1.39% | 3.38% | 1.86% | — | |
| $46.85 | $7.86B | -9999.00 | -5.25% | -0.02% | -0.02% | — |
Neuphoria Therapeutics Inc. (NEUP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neuphoria Therapeutics Inc. (NEUP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 23, 2026·SEC
May 26, 2026·SEC
Jan 8, 2026·SEC
Get notified when NEUP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neuphoria Therapeutics Inc. (NEUP) stock FAQ — growth, dividends, profitability & financials explained
Neuphoria Therapeutics Inc. (NEUP) reported $1.2M in revenue in fiscal year 2026, which is also its trailing twelve months.
Neuphoria Therapeutics Inc. (NEUP) revenue fell by 77.4% over the trailing twelve months, compared with the twelve months before.
No. Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $5.0M over the trailing twelve months.
Neuphoria Therapeutics Inc. (NEUP) had a return on equity (ROE) of -18.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Neuphoria Therapeutics Inc. (NEUP) had negative free cash flow of $9.7M over the trailing twelve months.